Metomide

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Metomide

Property Description
Active ingredient Metoclopramide hydrochloride
Form Tablet, Solution for injection, Oral solution
Pharmacological class Dopamine D2 receptor antagonist, Prokinetic agent, Anti-emetic
Common purpose Relief of nausea, vomiting, and impaired stomach movement
Origin Synthetic (Benzamide derivative)

What is Metomide and What Type of Drug is it?

Metomide is a synthetic, prescription-only medication whose active component is Metoclopramide hydrochloride. The drug is formally classified as both a prokinetic agent and a Dopamine D2 receptor antagonist. This means the medicine is designed to influence both digestive tract movement and the body's anti-vomiting mechanisms. The medication belongs chemically to the Benzamide derivatives. Metoclopramide is clinically recognized for its established efficacy in alleviating symptoms of nausea.


Composition, Origin, and Available Forms

The medication is a single-ingredient product derived from a synthetic origin, containing Metoclopramide hydrochloride as its sole active substance. Metomide is manufactured in multiple pharmaceutical preparations, which is a key differentiator from medications available only in a single form. These preparations include the oral tablet and the oral solution, intended for swallowing, as well as a solution for injection (parenteral) that allows for direct administration via the intravenous or intramuscular route. The composition of the liquid forms typically involves the active ingredient dissolved in an aqueous solution, while the tablets utilize solid excipients.


High-Level Purpose: How Does Metomide Generally Help?

Metomide generally helps to relieve symptoms associated with nausea, vomiting, and impaired stomach movement by working simultaneously on the digestive muscles and the brain's control mechanisms. The medicine's purpose stems from its prokinetic action, which increases the tone of the lower esophageal sphincter (LES) and accelerates gastric emptying. The medication's mechanisms include increasing stomach contractions in cases of digestive stasis. This means the medication provides a therapeutic benefit by both suppressing the vomiting reflex and actively promoting more normalized digestive tract function.

What side effects are possible with Metomide?

Metomide's official safety profile is significantly defined by the risk of adverse reactions affecting the Nervous System and the conditions governing its use duration. The occurrence of side effects is formally classified according to regulatory standards.

Official Adverse Reaction Classifications

Frequency Examples of Officially Documented Adverse Reactions
Very Common Drowsiness, Fatigue, Restlessness
Common Diarrhea, Headache, Hypotension, Depression
Not Known Tardive Dyskinesia (TD), Neuroleptic Malignant Syndrome (NMS), Cardiac Arrest, Circulatory Collapse

Serious Safety Considerations

The most serious documented safety concerns include Tardive Dyskinesia (TD), a potentially irreversible movement disorder, and the rare but life-threatening Neuroleptic Malignant Syndrome (NMS). Severe cardiovascular events, such as cardiac arrest and circulatory collapse, are listed, particularly following rapid intravenous administration. Acute Dystonic Reactions (involuntary muscle spasms) are also documented, with a higher incidence in children and young adults.

Safety Constraints and Population Notes

The risk of Tardive Dyskinesia is formally documented to increase with the duration of treatment and total cumulative dose. Treatment exceeding 12 weeks is generally avoided in the regulatory framework. The official labeling mandates dose reduction for patients with renal or severe hepatic impairment. The medicine is contraindicated in conditions like gastrointestinal hemorrhage, mechanical obstruction, or pheochromocytoma, as these represent high-risk scenarios documented in official sources.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Metomide is officially documented to primarily involve the central nervous system (CNS) and motor control. Manifestations typically include drowsiness, disorientation, and lethargy. The appearance of movement disorders, specifically Extrapyramidal Reactions (EPS), and seizures (convulsions) are also documented signs of overdosage. Regulatory information notes that these symptoms are often self-limiting, typically resolving within 24 hours.

Severe Outcomes and Help-Seeking Mandates

Two severe outcomes are officially recognized: Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex, and Methemoglobinemia, a blood disorder primarily reported in neonates following high-dose exposure. The occurrence of severe symptoms, such as collapse, trouble breathing, seizures, or signs of NMS (like muscle rigidity or high fever), mandates that immediate medical attention must be sought.

Management and Specific Interventions

Management is based on symptomatic and supportive treatment, as there is no specific general antidote. Supportive measures for EPS may include anticholinergic or antiparkinson drugs. Methylene blue is the documented intervention for treating Methemoglobinemia. Official labeling also indicates that neonates and young adults are noted as populations potentially more susceptible to certain overdose manifestations, such as Methemoglobinemia and acute EPS, respectively.

Therapeutic Uses of Metomide

The therapeutic uses of Metomide are relevant for managing symptoms related to gastrointestinal function and sickness. The medication is commonly applied in scenarios where additional management of discomfort is required, such as managing episodes of vomiting and nausea induced by chemotherapy, radiotherapy, or those occurring post-surgery. This supports the patient during difficult episodes by easing distress, especially in contexts involving heightened systemic burden.

The conditions for which Metomide is considered relevant include diabetic gastroparesis, symptomatic Gastroesophageal Reflux Disease (GERD), and sickness associated with acute migraine headache. It is also used in procedural contexts, such as facilitating small bowel intubation and promoting gastric emptying for radiological exams. The medication is applicable within clinical settings that involve acute or disruptive symptom patterns.

It is relevant for managing symptoms that interfere with daily comfort, including persistent heartburn and associated nausea. This provides supportive relief when symptoms interfere with routine activities, helping patients cope more steadily with symptom fluctuations.


Quick Fact: Symptomatic Support for Digestion and Sickness

Metomide helps address symptom clusters that may become intense or disruptive, including recurrent nausea, chronic vomiting, and the bothersome feeling of early fullness. This assists with maintaining functional stability, which contributes to improved comfort during periods of heightened symptoms.

Regulatory References

  1. NIH MedlinePlus overview on Metoclopramide

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Metomide

Metomide (Metoclopramide hydrochloride) eligibility is strictly governed by regulatory status, age, and existing medical conditions, with no use permitted outside of approved indications.

Populations Who Must Not Use Metomide (Contraindicated):

Condition / Population Restriction
GI Status Gastrointestinal hemorrhage, mechanical obstruction, or perforation
Neurological Epilepsy/Seizure Disorders, Parkinson's Disease, or history of metoclopramide-induced Tardive Dyskinesia
Endocrine Confirmed or suspected Pheochromocytoma
Co-Medication Patients taking Levodopa or Dopaminergic Agonists
Age Children less than 1 year of age

Eligibility Limitations and Special Considerations:

  • Children and Adolescents (1–18 years): Use is generally restricted to specific second-line indications, such as delayed Chemotherapy-Induced Nausea and Vomiting (CINV).
  • Organ Impairment: Patients with severe hepatic or renal impairment require a formal dose reduction (e.g., 50% for severe hepatic impairment; 75% for end-stage renal disease) to avoid accumulation.
  • Older Adults: A dose reduction should be considered based on overall frailty and kidney/liver function.
  • Pregnancy and Lactation: Use during late pregnancy is generally avoided. The medicine is not recommended for use by breastfeeding mothers.

What should I know about interactions with other medicines?

Metomide can interact with a wide range of other medicines and substances. These interactions can affect how Metomide works or increase the risk of side effects, particularly those affecting the brain and nervous system.

Key Interacting Medicines and Substances

  • Antipsychotics and Dopamine-Affecting Drugs: Concomitant use with antipsychotic medicines, other drugs known to cause extrapyramidal symptoms (EPS), or drugs that increase dopamine levels (such as levodopa) is generally avoided. Combining these can increase the risk of severe movement disorders like Tardive Dyskinesia (TD) and EPS.
  • Central Nervous System (CNS) Depressants: Alcohol, sedatives, opiates (narcotic analgesics), and hypnotics can cause additive effects with Metomide, leading to increased drowsiness, sedation, and reduced alertness. Use with these products should be monitored closely.
  • Anticholinergic Drugs: These medicines, which can slow down gut movement, may counteract the prokinetic (pro-motility) effect of Metomide. This can reduce the effectiveness of Metomide.
  • CYP2D6 Inhibitors: Metomide is processed by the liver enzyme CYP2D6. Strong inhibitors of this enzyme (e.g., certain antidepressants like fluoxetine or paroxetine) can increase the amount of Metomide in the body, potentially requiring a dose reduction of Metomide to minimize side effects.
  • Insulin and Digoxin: Metomide's action of speeding up stomach emptying can alter the absorption rate of other oral medicines, such as digoxin, and can affect blood sugar control in diabetic patients using insulin, sometimes necessitating an adjustment in insulin timing or dose.

Mechanism of Action

Central Modulation: Interfering with Emetic Signal Transmission

The molecule acts by directly blocking Dopamine (D2) and Serotonin (5-HT3) receptors located in the brain's Chemoreceptor Trigger Zone (CTZ). This antagonistic action interferes with the signaling pathway that receives chemical triggers from the blood, disrupting the neurological cascade that activates the vomiting center.


Peripheral Modulation: Increasing Gastrointestinal Motility

In the gut, the molecule works to increase natural movement by stimulating the Serotonin 5-HT4 receptors on enteric nerve cells and blocking peripheral D2 receptors. This dual mechanism increases the local release of Acetylcholine, which enhances the force and coordination of smooth muscle contractions, leading to an increased gastric emptying rate and elevated muscular tone in the lower esophagus.


Mechanistic Constraints

The peripheral prokinetic mechanism relies on the functional integrity of the enteric nervous system and its muscle tissue. Consequently, the capacity to increase propulsive muscular force may be physiologically constrained in conditions involving advanced nerve or muscle damage in the digestive tract.

Dosage and Administration Information

Metomide is approved for administration through both oral routes, available as tablets and solutions, and parenteral routes, via intravenous (IV) and intramuscular (IM) injection. Standard adult dosing for acute symptomatic use is typically 10 mg up to three times daily, though total daily intake must not exceed 30 mg or 0.5 mg/kg body weight. For gastrointestinal indications like diabetic gastroparesis, the dosing schedule requires 10 mg to be taken four times daily, with instructions to administer the dose 30 minutes before each meal and at bedtime.

The administration protocol mandates a minimal interval of 6 hours between any two doses, irrespective of whether the patient vomits after a dose. This procedural constraint is essential for preventing drug accumulation. Furthermore, the overall duration of use is strictly limited. Treatment for acute episodes has a maximum recommended duration of 5 days, while longer-term regimens for chronic conditions are typically restricted to 4 to 12 weeks.

Population-specific adjustments are mandatory for proper use. Patients with known renal or hepatic impairment require a dose reduction, typically a 50% decrease, due to altered drug clearance. Intravenous doses must be administered as a slow bolus over at least 3 minutes. If a scheduled dose is missed, instructions specify that the dose should be skipped and the regular schedule maintained; a double dose must never be taken.

Recent Clinical Evidence

Research evidence / Overview of studies for Metomide

Evidence for use in Controlling Nausea and Vomiting After Chemotherapy

Metomide was studied for use in patients facing nausea and vomiting after receiving cancer chemotherapy. The research in this area primarily consists of clinical trials that examined the use of Metomide in relation to patterns of nausea and vomiting experienced by patients. These trials typically tracked how symptoms evolved over short-term symptom changes following the chemotherapy session.

The findings from these trials describe patterns observed in the studies related to outcomes related to physical discomfort. Research highlights changes measured during the study period for outcomes capturing phases of heightened symptom activity. However, the overall evidence quality varies across studies, and it is not fully established how consistent the observed patterns were across the various chemotherapy agents studied, or across different study protocols.

Evidence for use in Managing Gastrointestinal Motility Issues

Metomide was evaluated in settings involving motility issues, particularly in conditions marked by functional limitations of the digestive tract. Research explored the results related to Metomide and outcomes reflecting daily functioning or activity level in patients. The available data describe patterns related to how the movement of food through the stomach and intestines was measured during the study period.

Studies report how symptoms evolved in the observed populations, specifically looking at outcomes related to physical discomfort such as feelings of fullness and bloating. The research is still emerging regarding the breadth of conditions where Metomide was evaluated in relation to motility. Sample sizes were modest in some studies, and long-term effects are not fully established.

What is still uncertain about Metomide

Key areas related to Metomide remain uncertain or require further study. Comparative evidence is lacking to fully understand how Metomide compares to other treatment options in terms of outcomes reflecting daily functioning or activity level. Research suggests the evidence is limited for many special populations, and data for certain groups remain insufficient. For most indications, follow-up durations were limited, meaning long-term effects are not fully established.

Key Studies & References

  1. Metoclopramide in the treatment of diabetic gastroparesis (Systematic Review)

Frequently Asked Questions (FAQ)

Common questions about Metomide (FAQ)

Q: How quickly can someone expect Metomide to start working?

Regulatory documents indicate that relief from nausea symptoms may begin early in the course of treatment. Official information suggests that symptom improvement may continue over a period of approximately three weeks.

Q: Is it common for doctors to adjust the Metomide dose over time?

Authoritative patient information describes dose adjustment as a possibility based on individual patient circumstances. This is often done based on individual needs and how the medicine is affecting them.

Q: Is Metomide a long-term or short-term treatment?

Metomide is officially specified as a short-term treatment. Due to the potential for the risk of a serious movement disorder (Tardive Dyskinesia) to increase with treatment duration, official regulatory constraints limit use to generally not exceed 12 weeks.

Q: Can Metomide interact with herbal remedies, like St. John's wort?

Official guidance advises caution regarding complementary medicines, herbal remedies, and other supplements. There is often not enough information to confirm these products are safe to use with Metomide, and some may potentially worsen side effects. Official guidance emphasizes the importance of sharing information about all supplements with a healthcare provider.

Q: Are there any common long-term side effects associated with Metomide?

The primary safety concern documented with longer treatment duration and total cumulative dose is the risk of Tardive Dyskinesia. This potentially irreversible movement disorder is the major factor in the official restriction on long-term use.

Q: What supplements should be avoided while taking Metomide?

Official guidance advises caution with supplements because there is not enough information to confirm their safety when combined with Metomide. Official guidance emphasizes the importance of sharing information about all supplements with a healthcare provider.

Q: What is the safety classification of Metomide for pregnancy?

The official product information describes the risk of the drug causing malformations when used by pregnant women as low. However, its use during the first and third trimesters is often avoided when possible, as documented in safety information.

Q: Can taking Metomide make a person feel tired or drowsy?

Yes, official documentation lists drowsiness and fatigue among the very common or common reported side effects. Patients should be aware of these potential effects when using the medicine.

Q: Are there any foods or drinks that should be strictly avoided with Metomide?

Official safety information states that alcohol may increase nervous system side effects, such as dizziness and drowsiness, and is generally to be avoided or limited. Other specific food restrictions are typically not listed.

Q: Does research show Metomide has been studied in children?

Yes, official regulatory bodies have reviewed data, including scientific reports on efficacy studies, for Metomide's use in children and adolescents. Its use in this population is generally restricted to specific, limited indications.

Q: Is there evidence that Metomide is a long-term solution?

Evidence supports its use only as a short-term treatment, with official regulatory constraints advising against use for longer than 12 weeks due to the risk of developing a serious movement disorder over time.

Q: Why might a person feel dizzy when starting Metomide?

Dizziness is listed in the official documentation among the common side effects that have been reported by people using Metomide. This is a known aspect of the drug's safety profile.

Q: Does Metomide affect hormone levels?

Official information states that Metomide can increase the level of the hormone prolactin in the blood. This increase may be associated with other physical effects documented in the safety profile.

Q: Does Metomide change how other medications are absorbed in the body?

Yes, because Metomide works to increase stomach movement (known as prokinetic action), it can alter the rate at which other medications taken by mouth are absorbed into the body.

Q: Can Metomide cause problems with vision?

Serious eye symptoms have been reported as part of the drug’s safety profile, which can include symptoms such as blurred vision or sudden changes in sight. The safety profile indicates patients should report any unexpected visual changes.

Q: Does Metomide affect fertility?

The drug has been reported to cause an increase in the hormone prolactin, which may be associated with menstrual problems or fertility issues. This effect is noted in authoritative patient resources.

Q: Are there any known interactions between Metomide and common cold medications?

Metomide can interact with a wide range of medicines, including ingredients commonly found in cold remedies. Since cold medicines often contain ingredients classified as CNS depressants, combining them with Metomide can potentially lead to increased drowsiness or other side effects.

Q: Is Metomide considered a controlled substance?

No, according to official classification documents and regulatory agencies, Metomide is not a controlled substance.

Q: Can Metomide make existing anxiety symptoms worse?

Authoritative patient safety information indicates that changes in mood and behavior have been reported, which may include new or increased feelings of anxiety. Depression is also listed as a common side effect.

How should Metomide be stored and disposed of?

Storage and Disposal of Metomide (Metoclopramide)

Requirement Type Official Regulatory Guidance
Temperature & Environment Store oral forms at room temperature, away from heat, moisture, and direct light. The oral solution must not store above 25 C and must be kept from freezing.
Handling & Stability Keep the oral solution in its original outer carton and use within one month of first opening. Metoclopramide Injection is light sensitive; single-use vials require the discarding of any unused portion.
Child Safety All forms must be kept out of the sight and reach of children.
Disposal Instructions Dispose of expired or unused medicine through a drug take-back program. Medicines should generally not be thrown away via wastewater. If a take-back program is unavailable, mix the product with an undesirable substance in a sealed container and place it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Metomide found in:

A-Z Index: